SOPHiA GENETICS Announces Key Approvals at 2025 Annual General Meeting

SOPHiA GENETICS ( (SOPH) ) has provided an announcement.

On June 18, 2025, SOPHiA GENETICS SA held its annual general meeting where shareholders approved several key items, including the 2024 Management Report and financial statements, ESG Impact Summary, and the discharge of the board and executive committee from liability for 2024. The meeting also saw the re-election of board members and the approval of compensation packages for the board and executive committee. Amendments to the Articles of Association were also approved, which included changes to the capital range and conditional share capital. These decisions reflect strong shareholder support and are likely to impact the company’s strategic direction and financial management.

The most recent analyst rating on (SOPH) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.

Spark’s Take on SOPH Stock

According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.

SOPH’s overall stock score is primarily driven by positive earnings call insights, showcasing revenue growth and strategic advancements. However, this is offset by weak financial performance, poor technical indicators, and alarming valuation metrics, which highlight profitability and operational challenges.

To see Spark’s full report on SOPH stock, click here.

More about SOPHiA GENETICS

SOPHiA GENETICS SA is a Swiss company operating in the field of genetic data analysis. The company specializes in the management, preservation, and storage of various types of archives, particularly in the genetic domain. It offers systems, products, and services related to data archiving and has a focus on developing, managing, and transferring licenses and franchise agreements.

Average Trading Volume: 41,704

Technical Sentiment Signal: Sell

Current Market Cap: $193.1M

See more insights into SOPH stock on TipRanks’ Stock Analysis page.